Tat peptide binding proteins and uses thereof
AssigneeLarimar Therapeutics, Inc.
InventorsXin XU, Erik Johan Wagner, Bonita Rup
Life of this patent
Estimating the term…
Abstract
The present invention encompasses TAT peptide binding proteins. Specifically, the invention relates to antibodies that specifically bind to a TAT protein transduction domain. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention for detection, quantification, purification and isolation of TAT protein transduction domain, e.g., a TAT fusion molecule comprising a TAT protein transduction domain, as well as methods of diagnosis and monitoring of HIV and AIDS are also provided herein.
Claims83
A binding protein comprising an antigen binding domain, said antigen binding domain comprising a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO:
- 4, wherein said binding protein is capable of binding a TAT protein transduction domain.
A binding protein comprising an antigen binding domain, said antigen binding domain comprising:
- a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 4, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 3, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 2;
- and
- a light chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 8, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 7, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 6;
- or a light chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 12, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 11, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 10,
- wherein said binding protein is capable of binding a TAT protein transduction domain.
A binding protein comprising an antigen binding domain, said antigen binding domain comprising a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO:
- 18, wherein said binding protein is capable of binding a TAT protein transduction domain.
A binding protein comprising an antigen binding domain, said antigen binding domain comprising:
- a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 18, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 17, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 16;
- and
- a light chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 22, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 21, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 20,
- wherein said binding protein is capable of binding a TAT protein transduction domain.
A binding protein comprising an antigen binding domain, wherein said binding protein is capable of binding to a TAT protein transduction domain that is covalently linked to a cargo moiety.
Dependencies are inferred from the claim text.